Evidence map›Paper›PMID 37947294›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2023

The effect of ibudilast on thalamic volume in progressive multiple sclerosis.

Showly Nicholson, Andrew W Russo, Kristina Brewer, Heidi Bien, Sean M Tobyne, Ani Eloyan, Eric C Klawiter

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Showly NicholsonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Andrew W RussoDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kristina BrewerDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Heidi BienDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sean M TobyneDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ani EloyanDepartment of Biostatistics, Brown University, Providence, RI, USA.
Eric C KlawiterDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · USBrown University · US

Funding

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical TrialU01NS077179 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Merit E CUDKOWICZ, Aleksandar Videnovic · 2011 to 2026
$43.4M
Network of Excellence in Neuroscience Clinical Trials (NEXT)-DCCU01NS077352 · NINDS · UNIVERSITY OF IOWA · PI CHRISTOPHER S. COFFEY · 2011 to 2026
$28.1M
Ibudilast Phase II trial in progressive MSU01NS082329 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI FOX, ROBERT J. · 2013 to 2017
$12.5M
Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS)U24NS107166 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Paula R Clemens · 2018 to 2026
$3.3M
NINDS NIH HHS U01 NS077179NINDS NIH HHS U01 NS077352NINDS NIH HHS U01 NS082329NINDS NIH HHS U24 NS107166
6 · The paper itself

Abstract

backgroundThalamic volume loss is known to be associated with clinical and cognitive disability in progressive multiple sclerosis (PMS).

objectiveTo investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS]).

methodsA total of 231 participants were randomized to either ibudilast (

resultsThere was no significant difference in thalamic volumes between treatment groups. On exploratory analysis, participants with primary progressive multiple sclerosis (PPMS) on placebo had a 0.004% greater rate of thalamic atrophy than PPMS participants on ibudilast (

conclusionIn a phase 2 trial evaluating ibudilast in PMS, no treatment effect was demonstrated in preventing thalamic atrophy. Participants with PPMS exhibited a treatment effect that trended toward significance. Longitudinal changes in thalamic volume were related to worsening of physical and cognitive disability, highlighting this outcome's clinical importance.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveAtrophyBayes TheoremHumansIndolizinesPyrazolesibudilastIndolizinesPyrazolesatrophyIbudilastmultiple sclerosisthalamustreatment outcome

Identifiers

PMID37947294
PMCPMC10841081
OpenAlexW4388567717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.